Cannabix Technologies Receives Notice of Allowance from USPTO for Contactless Breath Analysis
June 17 2025 - 8:00AM
InvestorsHub NewsWire

Cannabix Technologies Receives Notice of
Allowance from USPTO for Contactless Breath Analysis
VANCOUVER, British Columbia, June 17, 2025 -- InvestorsHub
NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF)
(Frankfurt: 8CT) (the "Company or Cannabix") is pleased to report
that the United States Patent and Trademark Office (USPTO) has
issued a notice of allowance for patent application
No. 18/1729,658 entitled, "Contact-Free Breath Analysis Device and
Method" to the Company.
This patent application is centered on innovations made by
Cannabix and its dual mode contactless (and traditional mouthpiece)
breath capture and analysis technology. The technology has
wide-ranging utility and can be integrated into everyday
environments such as vehicles, workplaces, or public kiosks and
supports fast, reliable testing without requiring physical contact.
The technology can be used in unmanned breath devices, offering
real-time feedback through visual indicators and displays and is
well-suited for applications in law enforcement, workplace safety,
and public health monitoring. The system intelligently
adjusts its internal airflow and pump mechanisms based on the
sampling method, ensuring accurate and hygienic analysis.
This patent application further augments Cannabix's leadership
position at the forefront of breath sampling and detection
techniques and continues to grow the intellectual capital of
Cannabix's breath capture and analytics portfolio. It should be
noted that a notice of allowance from the USPTO
does not constitute a grant of patent. The Company will report on
future material developments regarding its "Contact-Free Breath
Analysis Device and Method" patent application in due course.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and
alcohol breath technologies for workplaces, law enforcement and
other settings. Breath testing for delta-9 THC (the primary
psychoactive ingredient in cannabis) focuses on recent marijuana
use. Cannabix is the developer of
the BreathLogix autonomous alcohol screening
device for organizations who strive to improve alcohol safety and
monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking
statements" within the meaning of such statements under applicable
securities law. Forward-looking statements are frequently
characterized by words such as "anticipates," "plan," "continue,"
"expect," "project," "intend," "believe," "anticipate," "estimate,"
"may," "will," "potential," "proposed," "positioned" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements in this news
release include, but are not limited to, statements relating to
patent applications described in this news release; final
development of a commercial or prototype product(s); the successful
trial or pilot of company technologies; the commercialization of
the Company's products; the negotiation and potential entry into
additional agreements with distributors; and the completion of
future financings. There are numerous risks and uncertainties that
could cause actual results and the Company's plans and objectives
to differ materially from those expressed in the forward-looking
information. Important factors that could cause actual results to
differ materially from those expressed in the forward-looking
information include (but are note limited to): adverse market
conditions; risks regarding protection of proprietary technology;
the ability of the Company to complete future financings; the
ability of the Company to develop and market its future product;
risks regarding government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition;
that patent applications are not awarded by regulatory authorities;
that the CSE may not approve the issuance of the securities; that
the Company's development of breathalyzer technology will provide
any benefit to the Company; there is no assurance that any proposed
new products will be built, will be successful in beta testing or
clinical trials; there is no assurance that the Company will enter
into any partnerships to advance any of its corporate initiatives
or technologies; there is no assurance that any "patent pending" or
"provisional patents" technologies licensed by the Company or owned
by the Company will receive patent status by regulatory
authorities; the Company is not currently selling breathalyzers and
there is no assurance that the Company ever will; and other factors
beyond the control of the Company. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Jun 2025 to Jul 2025
Cannabix Technologies (PK) (USOTC:BLOZF)
Historical Stock Chart
From Jul 2024 to Jul 2025